Anavex Life Sciences (AVXL) Retained Earnings (2011 - 2025)

Anavex Life Sciences has reported Retained Earnings for 15 years, with the latest figure at -$388.1 million in Q4 2025.

• Quarterly Retained Earnings fell 11.47% year-over-year to -$388.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$388.1 million (down 11.47% YoY) and the FY2025 annual result came in at -$382.4 million, down 13.8% from the prior year.
• Retained Earnings declined to -$388.1 million in Q4 2025 per AVXL's latest filing, from -$382.4 million in the prior quarter.
• Over five years, Retained Earnings peaked at -$175.7 million in Q1 2021 and troughed at -$388.1 million in Q4 2025.
• A 5-year average of -$284.7 million and a median of -$288.0 million in 2023 frame the typical range for Retained Earnings.
• The sharpest annual moves came in 2022 and 2025: Retained Earnings declined 24.6% in 2022, then declined 11.47% in 2025.
• Over 5 years, Retained Earnings stood at -$208.5 million in 2021, then dropped by 24.02% to -$258.5 million in 2022, then retreated by 16.69% to -$301.7 million in 2023, then decreased by 15.41% to -$348.2 million in 2024, then fell by 11.47% to -$388.1 million in 2025.
• According to Business Quant data, Retained Earnings over the past three periods registered -$388.1 million, -$382.4 million, and -$372.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.